BridgeBio Pharma Reports Positive Results for Oral Infigratinib Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 28 2026
0mins
BridgeBio Pharma announced that positive results from PROPEL 3, the global Phase 3 study of oral infigratinib in children living with achondroplasia, were published as an original research article in the New England Journal of Medicine, NEJM. These data were also presented at the International Congress of Children's Bone Health, ICCBH, 2026 in a late-breaking oral presentation. The positive results shared in NEJM from PROPEL 3 include: PROPEL 3 successfully met the primary endpoint of change from baseline in annualized height velocity; PROPEL 3 successfully met the key secondary endpoint of change from baseline in height Z-score at Week 52; In a pre-specified exploratory analysis of the key secondary endpoint, oral infigratinib achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia; Infigratinib was well-tolerated, with: No discontinuations related to study drug, No serious adverse events related to study drug, 3 cases of hyperphosphatemia, all mild, transient, asymptomatic, and not requiring dose reductions or discontinuations, No adverse events associated with inhibition of FGFR1 or FGFR2. Additional data presented at ICCBH showed infigratinib improved arm span vs. placebo by +0.37 SD, marking the first statistically significant improvement in arm span from a placebo-controlled achondroplasia trial
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 77.750
Low
85.00
Averages
98.50
High
157.00
Current: 77.750
Low
85.00
Averages
98.50
High
157.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acoramidis Shows Kidney Protective Effects in ATTR-CM Patients
- Significant Kidney Protection: The initiation of acoramidis resulted in a 15.5% reduction in urinary albumin to creatinine ratio (UACR) by Day 28 (P<0.05) without any observed kidney-related adverse events, indicating its potential kidney-protective effects in patients with heart disease.
- Long-term Kidney Function Improvement: Over a 30-month period, acoramidis demonstrated a sustained increase in chronic estimated glomerular filtration rate (eGFR) of 2.47 mL/min/1.73m² per year (p<0.001) and a continued reduction in UACR (13.7%; p=0.026), highlighting its positive long-term impact on kidney function.
- Dual Cardiorenal Protection Mechanism: The mechanism of acoramidis resembles that of ACE inhibitors, ARBs, and SGLT2 inhibitors, potentially acting independently of TTR stabilization, suggesting its dual protective potential for both heart and kidney health, which may improve long-term survival rates.
- Significant Clinical Outcomes: Patients treated with acoramidis who experienced larger eGFR dips had a 58% lower risk of death or cardiovascular hospitalization within the first year (HR: 0.42; P=0.006), underscoring its importance in preventing cardiovascular events.
See More
Alnylam Pharmaceuticals Shares Drop 24%, Yet Optimism Persists
- Significant Revenue Growth: Alnylam Pharmaceuticals reported a 121% year-over-year surge in product revenue to $1.04 billion in Q1, primarily driven by a 153% increase in its ATTR franchise, indicating strong market demand in the rare disease treatment sector.
- Profitability Improvement: The company achieved earnings per share (EPS) of $1.51, a substantial turnaround from a loss of $0.14 per share in the same period last year, demonstrating Alnylam's rapid transition into a profitable commercial powerhouse, which boosts investor confidence.
- Expansion into New Indications: New data for Alnylam's Amvuttra reinforces its position as a first-line treatment for cardiomyopathy, setting the stage for a massive commercial launch and further market share expansion.
- Strong Technological Moat: Alnylam's RNA interference platform creates a deep technological moat, and its collaboration with Inceptive Nucleics on AI accelerates the discovery of next-generation RNAi structures, ensuring its competitive edge in the biotech industry.
See More
Alnylam Pharmaceuticals Reports Strong Q1 Performance
- Significant Revenue Growth: Alnylam Pharmaceuticals reported a 121% year-over-year surge in product revenue to $1.04 billion in Q1, primarily driven by a 153% increase in its transthyretin amyloidosis (ATTR) franchise, indicating strong market demand in the rare disease treatment sector.
- Profitability Improvement: The company achieved earnings per share (EPS) of $1.51, a substantial turnaround from a loss of $0.14 per share in the same period last year, marking a significant improvement in profitability and showcasing its transition from a high-burn clinical biotech to a profitable commercial powerhouse.
- Broad Market Outlook: Alnylam's guidance for full-year 2026 net product revenue ranges between $4.9 billion and $5.3 billion, reflecting a 71% year-over-year growth at the midpoint, highlighting the company's potential to penetrate mainstream high-volume therapeutic markets, particularly in cardiomyopathy and hypertension.
- Strong Technological Moat: Alnylam's RNA interference (RNAi) drug delivery system creates a deep technological moat, and its strategic AI collaboration with Inceptive Nucleics accelerates the discovery of next-generation RNAi structures, ensuring the company's competitive edge in the rapidly evolving biotech landscape.
See More
BridgeBio Pharma Secures $1B Investment in Convertible Preferred Equity
- Financing Agreement: BridgeBio Pharma announced an agreement with funds managed by Sixth Street and HealthCare Royalty, securing up to $1 billion in newly issued convertible preferred equity, reflecting strong market confidence in its future growth.
- Preferred Stock Terms: The Series A cumulative convertible preferred stock features a 7.00% initial dividend, payable in cash or kind at the company's discretion, enhancing the flexibility of its capital structure.
- Investor Contributions: Sixth Street funded $800 million as the lead investor, while HealthCare Royalty contributed $133.9 million, providing robust support for BridgeBio's R&D and market expansion efforts.
- Advisory Support: Latham & Watkins served as legal counsel for BridgeBio, with Evercore providing financial advisory services, ensuring the smooth execution of the transaction and reflecting the company's expertise in capital market operations.
See More
BridgeBio Secures $1 Billion Preferred Equity Investment
- Large Financing Round: BridgeBio has entered into an agreement with Sixth Street and HealthCare Royalty to secure up to $1 billion in newly issued convertible preferred equity, with an initial conversion price of approximately $138 per share, representing over a 100% premium to the company's 30-day volume-weighted average price, significantly strengthening the company's capital structure.
- Strategic Timing: This financing occurs at a pivotal moment as the Attruby® drug continues to grow into a multi-billion-dollar blockbuster, while BridgeBio prepares for three additional potential blockbuster U.S. product launches over the next 12 months, ensuring the company's competitive edge in the market.
- Investor Confidence: Sixth Street funded $800 million as the lead investor, while HealthCare Royalty contributed $133.9 million, demonstrating strong confidence in BridgeBio's management team and its ability to develop transformative therapies, further solidifying the company's market position.
- Future Outlook: This financing not only provides BridgeBio with flexible capital support but also lays the groundwork for future product launches and market expansion, expected to drive the company's continued growth in addressing high unmet medical needs.
See More
KKR and Sixth Street Partners Invest $1B in BridgeBio Pharma
- Financing Amount: KKR and Sixth Street Partners have reportedly agreed to provide $1 billion in preferred equity to biotechnology firm BridgeBio Pharma, with an announcement expected as soon as Wednesday, aimed at accelerating the launch of new drugs for genetic diseases.
- Market Reaction: BridgeBio Pharma's shares fell 1.4% in after-hours trading and are approximately 3% lower year-to-date, reflecting a cautious market response to the financing news.
- Strategic Importance: This financing will provide BridgeBio with the necessary capital to advance its drug development efforts, particularly in the genetic disease treatment sector, potentially enhancing its competitive position in the market.
- Industry Outlook: With the growing demand for treatments for genetic diseases, this funding will help BridgeBio secure a more advantageous position in the rapidly evolving biotechnology market, further attracting investor interest.
See More
Acoramidis Shows Kidney Protective Effects in ATTR-CM Patients
- Significant Kidney Protection: The initiation of acoramidis resulted in a 15.5% reduction in urinary albumin to creatinine ratio (UACR) by Day 28 (P<0.05) without any observed kidney-related adverse events, indicating its potential kidney-protective effects in patients with heart disease.
- Long-term Kidney Function Improvement: Over a 30-month period, acoramidis demonstrated a sustained increase in chronic estimated glomerular filtration rate (eGFR) of 2.47 mL/min/1.73m² per year (p<0.001) and a continued reduction in UACR (13.7%; p=0.026), highlighting its positive long-term impact on kidney function.
- Dual Cardiorenal Protection Mechanism: The mechanism of acoramidis resembles that of ACE inhibitors, ARBs, and SGLT2 inhibitors, potentially acting independently of TTR stabilization, suggesting its dual protective potential for both heart and kidney health, which may improve long-term survival rates.
- Significant Clinical Outcomes: Patients treated with acoramidis who experienced larger eGFR dips had a 58% lower risk of death or cardiovascular hospitalization within the first year (HR: 0.42; P=0.006), underscoring its importance in preventing cardiovascular events.
See More
Alnylam Pharmaceuticals Shares Drop 24%, Yet Optimism Persists
- Significant Revenue Growth: Alnylam Pharmaceuticals reported a 121% year-over-year surge in product revenue to $1.04 billion in Q1, primarily driven by a 153% increase in its ATTR franchise, indicating strong market demand in the rare disease treatment sector.
- Profitability Improvement: The company achieved earnings per share (EPS) of $1.51, a substantial turnaround from a loss of $0.14 per share in the same period last year, demonstrating Alnylam's rapid transition into a profitable commercial powerhouse, which boosts investor confidence.
- Expansion into New Indications: New data for Alnylam's Amvuttra reinforces its position as a first-line treatment for cardiomyopathy, setting the stage for a massive commercial launch and further market share expansion.
- Strong Technological Moat: Alnylam's RNA interference platform creates a deep technological moat, and its collaboration with Inceptive Nucleics on AI accelerates the discovery of next-generation RNAi structures, ensuring its competitive edge in the biotech industry.
See More
Alnylam Pharmaceuticals Reports Strong Q1 Performance
- Significant Revenue Growth: Alnylam Pharmaceuticals reported a 121% year-over-year surge in product revenue to $1.04 billion in Q1, primarily driven by a 153% increase in its transthyretin amyloidosis (ATTR) franchise, indicating strong market demand in the rare disease treatment sector.
- Profitability Improvement: The company achieved earnings per share (EPS) of $1.51, a substantial turnaround from a loss of $0.14 per share in the same period last year, marking a significant improvement in profitability and showcasing its transition from a high-burn clinical biotech to a profitable commercial powerhouse.
- Broad Market Outlook: Alnylam's guidance for full-year 2026 net product revenue ranges between $4.9 billion and $5.3 billion, reflecting a 71% year-over-year growth at the midpoint, highlighting the company's potential to penetrate mainstream high-volume therapeutic markets, particularly in cardiomyopathy and hypertension.
- Strong Technological Moat: Alnylam's RNA interference (RNAi) drug delivery system creates a deep technological moat, and its strategic AI collaboration with Inceptive Nucleics accelerates the discovery of next-generation RNAi structures, ensuring the company's competitive edge in the rapidly evolving biotech landscape.
See More
BridgeBio Pharma Secures $1B Investment in Convertible Preferred Equity
- Financing Agreement: BridgeBio Pharma announced an agreement with funds managed by Sixth Street and HealthCare Royalty, securing up to $1 billion in newly issued convertible preferred equity, reflecting strong market confidence in its future growth.
- Preferred Stock Terms: The Series A cumulative convertible preferred stock features a 7.00% initial dividend, payable in cash or kind at the company's discretion, enhancing the flexibility of its capital structure.
- Investor Contributions: Sixth Street funded $800 million as the lead investor, while HealthCare Royalty contributed $133.9 million, providing robust support for BridgeBio's R&D and market expansion efforts.
- Advisory Support: Latham & Watkins served as legal counsel for BridgeBio, with Evercore providing financial advisory services, ensuring the smooth execution of the transaction and reflecting the company's expertise in capital market operations.
See More
BridgeBio Secures $1 Billion Preferred Equity Investment
- Large Financing Round: BridgeBio has entered into an agreement with Sixth Street and HealthCare Royalty to secure up to $1 billion in newly issued convertible preferred equity, with an initial conversion price of approximately $138 per share, representing over a 100% premium to the company's 30-day volume-weighted average price, significantly strengthening the company's capital structure.
- Strategic Timing: This financing occurs at a pivotal moment as the Attruby® drug continues to grow into a multi-billion-dollar blockbuster, while BridgeBio prepares for three additional potential blockbuster U.S. product launches over the next 12 months, ensuring the company's competitive edge in the market.
- Investor Confidence: Sixth Street funded $800 million as the lead investor, while HealthCare Royalty contributed $133.9 million, demonstrating strong confidence in BridgeBio's management team and its ability to develop transformative therapies, further solidifying the company's market position.
- Future Outlook: This financing not only provides BridgeBio with flexible capital support but also lays the groundwork for future product launches and market expansion, expected to drive the company's continued growth in addressing high unmet medical needs.
See More
KKR and Sixth Street Partners Invest $1B in BridgeBio Pharma
- Financing Amount: KKR and Sixth Street Partners have reportedly agreed to provide $1 billion in preferred equity to biotechnology firm BridgeBio Pharma, with an announcement expected as soon as Wednesday, aimed at accelerating the launch of new drugs for genetic diseases.
- Market Reaction: BridgeBio Pharma's shares fell 1.4% in after-hours trading and are approximately 3% lower year-to-date, reflecting a cautious market response to the financing news.
- Strategic Importance: This financing will provide BridgeBio with the necessary capital to advance its drug development efforts, particularly in the genetic disease treatment sector, potentially enhancing its competitive position in the market.
- Industry Outlook: With the growing demand for treatments for genetic diseases, this funding will help BridgeBio secure a more advantageous position in the rapidly evolving biotechnology market, further attracting investor interest.
See More
